Less Ads, More Data, More Tools Register for FREE

Pin to quick picksApax Global Alpha Regulatory News (APAX)

  • This share is currently suspended. It was suspended at a price of 164.40
  • There is currently no data for APAX

Form 8.3 - APAX LN

8 Aug 2025 15:00

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Sand Grove Capital Management LLP

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

Fund(s) for which Sand Grove Capital Management LLP serves as the Investment Manager or Discretionary Sub-Advisor

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Apax Global Alpha Limited

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

07 August 2025

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

N/A

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

Ordinary NPV

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

10,885,047

2.26%

(2) Cash-settled derivatives:

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

10,885,047

2.26%

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

Number of securities

Price per unit

Ordinary NPV

Purchase

744,334

1.88537 EUR

Ordinary NPV

Purchase

485,184

163.5p

Ordinary NPV

Purchase

270,483

163.5p

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None

(c) Attachments

Is a Supplemental Form 8 (Open Positions) attached?

No

Date of disclosure:

08 August 2025

Contact name:

James Evans

Telephone number:

+44 20 3161 0743

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129.

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel’s Market Surveillance Unit.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250808968083/en/

Copyright Business Wire 2025

Date   Source Headline
14th Mar 20197:00 amRNSNotice of AGM
13th Mar 20196:05 pmRNSDirector/PDMR Shareholding
5th Mar 20197:00 amRNSUpdated Key Information Document
5th Mar 20197:00 amRNS2018 Annual Dividend
5th Mar 20197:00 amRNS2018 Annual Report and Accounts
5th Mar 20197:00 amRNS2018 Final Results
26th Feb 201911:42 amRNSExits from Exact Software and AssuredPartners
29th Jan 20197:00 amRNSApax Funds' Valuations as at 31 December 2018
21st Dec 20181:48 pmRNSDirector/PDMR Shareholding
21st Dec 201812:09 pmRNSInclusion in FTSE 250 Index
19th Dec 20186:30 pmRNSShire
27th Nov 201810:00 amRNSPDMR Dealing - Share Transfers
23rd Nov 20183:07 pmRNSDirector Dealings - Chris Ambler
14th Nov 20187:00 amRNSNotice of Annual Results
7th Nov 20187:00 amRNSNew revolving credit facility
7th Nov 20187:00 amRNSQuarterly results for the period ended 30 Sep 2018
13th Sep 20184:29 pmRNSDirector Dealings - Chris Ambler
5th Sep 20185:12 pmRNSNotice of Quarterly Results 30 Sept 2018
14th Aug 20187:00 amRNS2018 Interim Dividend
14th Aug 20187:00 amRNS2018 Interim Results Highlights
14th Aug 20187:00 amRNS2018 Interim Report and Accounts
31st Jul 20187:00 amRNSApax Funds' Valuations as at 30 June 2018
18th Jul 20183:00 pmRNSHolding(s) in Company
3rd Jul 201810:00 amRNSDirectorate Change
2nd Jul 20183:00 pmRNSDirector Declaration
14th Jun 20187:00 amRNSNotice of Interim Results 2018
6th Jun 20187:00 amRNSAGA Investor Day
23rd May 201810:00 amRNSEU GDPR Data Privacy Notices
3rd May 20187:00 amRNSQuarterly results for 31 March 2018
1st May 20183:04 pmRNSResult of AGM
26th Apr 201812:47 pmRNSDirectorate Change
16th Apr 20187:25 amRNSNotice of Investor Day
19th Mar 20184:46 pmRNSDirector Declaration
19th Mar 201812:00 pmRNSNotice of AGM
14th Mar 20182:45 pmRNSNotice of Quarterly Results Q1 2018
6th Mar 20187:00 amRNS2017 Annual Dividend Announcement
6th Mar 20187:00 amRNSUpdated Key Information Document
6th Mar 20187:00 amRNS2017 Final Results
6th Mar 20187:00 amRNS2017 Annual Report and Accounts
31st Jan 20185:25 pmRNSDirector/PDMR Shareholding
30th Jan 20187:00 amRNSApax Funds' Valuations as at 31 December 2017
4th Jan 20185:09 pmRNSDirectorate Change - Sarah Evans
2nd Jan 201812:00 pmRNSPublication of Key Information Document
15th Dec 20172:06 pmRNSHolding(s) in Company
6th Nov 20177:00 amRNSNotice of Annual Results
1st Nov 20177:00 amRNSQ3 2017 Results Highlights
11th Sep 20177:00 amRNS3Q17 Financial Highlights
31st Aug 20172:57 pmRNSAGA's FTSE Index Inclusion
17th Aug 20177:00 amRNS2017 Interim Dividend
17th Aug 20177:00 amRNS2017 Interim Report and Accounts

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.